Cellular Therapies tissue manipulation and clinical solutions Cell Therapies
 
Home
About
Facilities
Our Staff
News + Developments
Studies + Trials
Media + Publications
Cell Therapies delivers flexible solutions across the full spectrum of clinical trials involving cell and tissue manipulation
 
 
the Centre for Blood Cell Therapies Clean Rooms

Clean Room facilities include 23m2 high speed cell sorting laboratory suitable for research activities and a second high speed cell sorting clean room, 20m2, set-up for clinical cell sorting for patient use.

Loading an incubator in a Clean Room

The research sorting room is equipped with FACStar Plus FACS-DIVA and FACS-CALIBUR. R5 is utilized for clinical sorting and processing of patients, and is equipped with FACSVantage SE
Special laboratory features |

NEWS + DEVELOPMENTS
  1. Bid To Beat Toxic Anti Cancer Drugs
    A team of Melbourne doctors is working on a new cancer treatment that spares patients the unpleasant side effects of poisonous chemotherapy drugs.
    Article in the Melbourne AGE, February 22 2011
    Professor Miles Prince of the Peter MacCallum Cancer Centre and his colleagues are testing epigenetic drugs that switch off the controlling mechanisms of genes inside cancerous cells rather than killing them with toxic agents.

    --------------------------------------------------------------------------------

  2. Update on Peter Mac and CT Research Activities
    One of the most exciting aspects of being a researcher at Peter Mac is the opportunity to take discoveries from the lab to the clinic.
    October 2010
    Effective collaboration between laboratory and clinical researchers is vital for improving the outcomes of patients with cancer

    --------------------------------------------------------------------------------

  3. Clinical and Commercial Solutions
    Cell Therapies Pty Ltd brings world-best research and science together with astute commercial operations
    The key to the Celll Therapies Pty Ltd’s success is its attention to the needs of researchers and clinicians, in combination with the commercial imperatives of bringing a new therapy to market

    --------------------------------------------------------------------------------

  4. Mesoblast Applies For TGA Licence
    Mesoblast to Apply for Regulatory Approval of its Bone Fracture Repair Products
    Melbourne, Australia, July 2009
    Earlier Revenues Anticipated Through Distribution To Australian Hospitals And Clinicians

    --------------------------------------------------------------------------------

  5. Cell Therapies P/L Secures NCRIS Subsidies for its Clients
    Research Infrastructure Support Services (RISS) announced that Cell Therapies (CT) has been awarded subsidies of up to 50% for eligible expenditures being incurred by three clients.
    Dec/2008
    CT also received a $50,000 subsidy for the maintenance of its own TGA license.

    --------------------------------------------------------------------------------

  6. Research Grant
    A team at Peter MacCallum Cancer Centre recently received a Grant from the National Medical Health Research Council (NHMRC) of Australia.
    The $10.8 million Grant has been awarded to better understand the molecular basis of cell death and the complex cellular interactions involved in cell-mediated cancer immunity.

    --------------------------------------------------------------------------------

  7. New Lab Helps Translate Research
    A new lab within The Peter MacCallum Cancer Centre will allow seamless translation from research to full cGMP compliance and clinical application.
    The Haematology Immunology Translational Research Laboratory (HITRL) is a bridge between the Centre’s world-class cancer immunologists and clinical researchers within its Haematology Department, according to Dr David Ritchie, Deputy Director, Centre for Blood Cell Therapies (CBCT) at Peter MacCallum

    --------------------------------------------------------------------------------

  
 
Cellular Therapies tissue manipulation and clinical solutions Cell Therapies | Contact | Login | Site ex99elle
In association with Peter MacCallum Cancer Research - Genetics, Genomics and Biotechnology BioMelbourne Network - Progressing BioIndustry
Cell Therapies Pty Ltd ABN 100 285 916